prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |review
The CARE investigators were also able to demonstrate the long-term effects of pravastatin on reducing CRP. At baseline, CRP levels were identical in both the placebo- and pravastatin-treated groups. However, at the end of 5 years, CRP levels were markedly reduced with pravastatin. Similar data have now been shown for statins at as early as 1 year and perhaps as early as 6 to 8 weeks. 

Reference:
Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-235.
Web site